CD49d


Also found in: Wikipedia.

CD49d

a type I transmembrane protein present on B cells and T cells, natural killer cells, eosinophils, monocytes, erythroblasts, thymocytes, and myoblasts that facilitates cell-cell adhesion and leukocyte migration and aids in lymphocyte activation; expressed in melanomas.

CD49D

This term continues to be used amongst immunologists; the preferred designation in the HUGO database is ITGA4.
References in periodicals archive ?
ATL1102 is a second-generation antisense inhibitor of CD49d, an immune system protein known as VLA-4 (Very Late Antigen-4), and is currently in development as a treatment for MS.
ATL/TV1102 is a second generation anti-sense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4), and is currently in Phase IIa clinical trials as a treatment for MS.
New data on ATL/TV1102, a second generation antisense inhibitor of CD49d, a subunit of VLA-4, for the treatment of RRMS patients, will be presented as well.
Alternate theories of the mechanism of sequestration of IVLBCL to the intravascular space include deficient expression of receptors for peanut agglutinin and CD49d, both of which promote homing of tumor cells to endothelial cells via interaction with CD54 and CD106 (CD49d ligand).
is suggests that either the inhibition of CD49d was not complete or that other characteristics of CLL cells enable them to migrate out of the vascular system.
8,9) Additional positive markers include CD9, CD11c, CD29, CD33, CD43, CD44, CD45, CD49d, CD49e, CD51, CD54, CD71, and the high-affinity immunoglobulin E receptor.
In healthy subjects, particle exposure with exercise reduced expression of adhesion molecules CD54 and CD18 on monocytes and CD18 and CD49d on granulocytes.
Stimulation was performed with 40 [micro]L/mL (total protein content of approximately 1 [micro]g/mL) of vaccinia viral antigen resuspended according to the manufacturer's instructions (Maine Biotechnology Services, Portland, ME), or 2 [micro]g of CMV antigen (Biowhittaker, Walkersville, MD), always in the presence of co-stimulation with both anti-CD28 and CD49d monoclonal antibodies (1 [micro]g/mL, Becton, Dickinson and Company, Franklin Lakes, N J).
In addition, clinical data will be presented on the investigational compound ATL/ TV-1102, a second generation antisense inhibitor of CD49d, a subunit of VLA-4, for the treatment of RRMS patients.
ATL1102 is a 2nd generation antisense inhibitor of CD49d, a subunit of Very Late Antigen 4 (VLA-4) which plays a key role in cell adhesion to vessel walls.
FITC PE PE-Cy5 APC 1 [kappa] CD34 CD62L CD38 2 [kappa] CD14 CD44 CD38 3 [kappa] CD126 HLA-DR CD38 4 [kappa] CD117 CD128 CD38 5 [kappa] CD11b CD38 CD3 6 [kappa] CD184 CD38 CD19 7 [kappa] CD45ro CD38 CD10 8 [kappa] CD31 CD38 CD54 9 [kappa] CD50 CD38 CD49d 10 [kappa] CD130 CD38 CD44 11 [kappa] CD56 CD38 CD20 12 [lambda] CD34 CD62L CD38 13 [lambda] CD14 CD44 CD38 14 [lambda] CD126 HLA-DR CD38 15 [lambda] CD117 CD128 CD38 16 [lambda] CD11b CD38 CD3 17 [lambda] CD184 CD38 CD19 18 [lambda] CD45ro CD38 CD10 19 [lambda] CD31 CD38 CD54 20 [lambda] CD50 CD38 CD49d 21 [lambda] CD130 CD38 CD44 22 [lambda] CD56 CD38 CD20 Abbreviations: APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PE-Cy5, phycoerythrin-Cy5.